ABCD

DRUG4 trials

Sponsors

Foshan Chancheng Central Hospital, Prince of Songkla University, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CSPC Ouyi Pharmaceutical Co., Ltd.

Conditions

Anti-agingHealthyInvasive Fungal DiseaseInvasive Mold Disease

Early Phase 1

Clinical study on anti-aging effect of invigorating spleen and tonifying kidney combined with NK cells

Active, not recruitingITMCTR1900002801

Foshan Chancheng Central HospitalAnti-aging

Start: 2020-01-01Updated: 2023-02-20

Phase 1

The Safety of Tuberculosis Treatments by Oral Inhalation

Prince of Songkla UniversityHealthy

Start: 2013-02-28End: 2013-04-30Target: 40Updated: 2013-02-07

Single Dose Escalations Study of Amphotericin B Colloidal Dispersion In Healthy Subjects in China

CompletedNCT03577509

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Invasive Fungal Disease

Start: 2018-07-02End: 2018-09-14Updated: 2018-10-09

Phase 3

A Study to Evaluate the Safety, Efficacy, and PPK of ABCD in Patients With IMD

CompletedNCT07239765

CSPC Ouyi Pharmaceutical Co., Ltd.Invasive Mold Disease

Start: 2021-07-09End: 2024-04-29Updated: 2025-11-20

Related Papers

Pharmacokinetics and Safety of Single-Dose Amphotericin B Colloidal Dispersion in Healthy Chinese Subjects and Population Pharmacokinetic/Pharmacodynamic Analysis to Inform Clinical Efficacy in Invasive Infections Caused by Candida albicans.

2021-10-203 citations